135 related articles for article (PubMed ID: 4823081)
1. A clinical syndrome characteristic of primary Type IV-V hyperlipoproteinaemia.
Borrie P; Slack J
Br J Dermatol; 1974 Mar; 90(3):245-53. PubMed ID: 4823081
[No Abstract] [Full Text] [Related]
2. Type 3 hyperlipoproteinaemia.
Eisenberg S
Clin Endocrinol Metab; 1973 Mar; 2(1):111-25. PubMed ID: 4359114
[No Abstract] [Full Text] [Related]
3. Type IV hyperlipoproteinaemia.
Kwiterovich PO; Margolis S
Clin Endocrinol Metab; 1973 Mar; 2(1):41-71. PubMed ID: 4359117
[No Abstract] [Full Text] [Related]
4. Xanthomatosis and hyperlipoproteinemia; a review.
Polano MK
Dermatologica; 1974; 149(1):1-9. PubMed ID: 4372111
[No Abstract] [Full Text] [Related]
5. [Xanthomatosis as a symptom of hyperlipidemic metabolic disorders. Relationship of the morphological picture to the lipid of three patients].
Rufli T; Stähelin H
Dermatologica; 1972; 144(5):270-82. PubMed ID: 4351630
[No Abstract] [Full Text] [Related]
6. Type 3 hyperlipoproteinaemia.
Borrie P
Br Med J; 1969 Jun; 2(5658):665-7. PubMed ID: 5783124
[TBL] [Abstract][Full Text] [Related]
7. Type V hyperlipoproteinaemia.
Gotto AM
Clin Endocrinol Metab; 1973 Mar; 2(1):11-39. PubMed ID: 4359115
[No Abstract] [Full Text] [Related]
8. Xanthomatosis, hyperlipoproteinaemia (type II, Fredrickson), gout, cardiac infarction.
Storey GO
Proc R Soc Med; 1971 Jan; 64(1):59-60. PubMed ID: 5551460
[No Abstract] [Full Text] [Related]
9. Type IV hyperlipoproteinaemia. A survey based on 23 cases.
Christensen NC; Horder M
Dan Med Bull; 1970 Feb; 17(2):54-9. PubMed ID: 5446368
[No Abstract] [Full Text] [Related]
10. Polyneuropathy associated with hyperlipemia.
Bechar M; Kott E; Bornstein B
Confin Neurol; 1969; 31(5):281-8. PubMed ID: 5383223
[No Abstract] [Full Text] [Related]
11. Xanthomatosis associated with hyperlipoproteinemia.
Parker F; Short JM
J Invest Dermatol; 1970 Aug; 55(2):71-88. PubMed ID: 4923080
[No Abstract] [Full Text] [Related]
12. [Hyperlipidemia and other risk factors in coronary sclerosis].
Klör HU; Märtens HR; van Eimeren W; Härich B; Ditschuneit H
Arzneimittelforschung; 1972 Oct; 22(10):1808-10. PubMed ID: 4678569
[No Abstract] [Full Text] [Related]
13. [Xanthomatosis eruptiva papulosa (hyperlipoproteinemia type V)].
Vigh C; Czinder K; Mátyus L
Z Hautkr; 1974 Oct; 49(19):819-28. PubMed ID: 4464725
[No Abstract] [Full Text] [Related]
14. Heterogeneity on familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride-cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate.
Davignon J; Aubry F; Noël C; Lapierre Y; Lafortune M
Rev Can Biol; 1971 Dec; 30(4):307-18. PubMed ID: 5135408
[No Abstract] [Full Text] [Related]
15. Bilateral parotid gland enlargement and hyperlipoproteinemia.
Kaltreider HB; Talal N
JAMA; 1969 Dec; 210(11):2067-70. PubMed ID: 5395209
[No Abstract] [Full Text] [Related]
16. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
Gustafson A
Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
[No Abstract] [Full Text] [Related]
17. Xanthomata in primary hyperlipoproteinemia. A classification based on the lipoprotein pattern of the blood.
Polano MK; Baes H; Hulsmans HA; Querido A; Pries C; van Gent CM
Arch Dermatol; 1969 Oct; 100(4):387-400. PubMed ID: 5358101
[No Abstract] [Full Text] [Related]
18. Very low density lipoprotein subfractions in a subject with broad-beta disease (Type 3 hyperlipoproteinemia) and a subject with endogenous lipemia (Type IV). Chemical composition and electrophoretic mobility.
Hazzard WR; Lindgren FT; Bierman EL
Biochim Biophys Acta; 1970 May; 202(3):517-25. PubMed ID: 5442187
[No Abstract] [Full Text] [Related]
19. Studies in asymptomatic primary hyperlipidaemia II. Clinical findings.
Olsson AG
Acta Med Scand; 1975 Jun; 197(6):477-85. PubMed ID: 168737
[TBL] [Abstract][Full Text] [Related]
20. Essential hyperlipemia with xanthomatosis: effects of cholestyramine and clofibrate.
Roe DA
Arch Dermatol; 1968 Apr; 97(4):436-45. PubMed ID: 5643239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
